New insights into the developmental trajectory of social behaviors in fragile X syndrome

The FDA on Mon­day re­leased new­ly-re­vised guid­ance on ear­ly Alzheimer’s dis­ease drug de­vel­op­ment, in­clud­ing a sec­tion that boosts the case for us­ing amy­loid re­duc­tion as

Charles Riv­er’s over­all man­u­fac­tur­ing busi­ness saw a 9.5% de­crease in rev­enue in the last quar­ter of 2023 with $191.9 mil­lion, ver­sus $212.1 mil­lion in the

Spec­u­la­tion has been swirling in re­cent weeks over whether the Ger­man gener­ic drug com­pa­ny known as Sta­da might seek a sale worth about $11 bil­lion.